SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Geron Corp.
GERN 2.820-3.8%9:30 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Savant2/1/2013 1:52:06 AM
   of 3570
 
RT... LifeMap Sciences, a Subsidiary of BioTime, Announces Publication of Research
Report Describing Non-Redundant Compendium of Human Non-Coding RNA Authored by
GeneCards(R) Scientists

Report shows the existence of a^ 1/480,000 human non-redundant non-coding RNAs
covering 71% of the human genome, slightly less than the ENCODE prediction of 80%

ALAMEDA, Calif., Jan 30, 2013 (BUSINESS WIRE) -- LifeMap Sciences, Inc., a
subsidiary of BioTime, Inc. (nyse mkt:BTX), announced today the publication of a
paper authored by a research group under the supervision of Prof. Doron Lancet
from the Department of Molecular Genetics at the Weizmann Institute of Science
describing the analysis and display of a non-redundant compendium of human
non-coding RNA genes, which was made available as part of GeneCards(R) Version
3.09, released November 18, 2012. LifeMap Sciences holds the exclusive worldwide
license to market GeneCards(R) from Yeda Research and Development Company Ltd.,
the commercial arm of the Weizmann Institute of Science.

Non-coding RNA (ncRNA) genes are increasingly acknowledged for their importance
in the human genome, and are implicated in various disease processes. Therefore
they are of interest to many academic and industry researchers in various
biomedical fields, and to biotechnology and pharmaceutical companies engaged in
discovery and development of diagnostic and therapeutic products. The ENCODE
project Click for Detail, launched in 2003 has recently predicted
that ~80% of all genomic territories are transcribed in one fashion or another.
In the GeneCards(R) publication, in the journal Bioinformatics
Click for Detail, the scientists leveraged the
effective platform of GeneCards(R) to unify all ncRNA gene entries obtained from
15 different primary data sources. Overlapping entries were clustered to unified
locations based on an algorithm employing genomic coordinates, resulting in a a^
1/45-fold increase, to a total of a^ 1/480,000 human non-redundant ncRNAs,
belonging to 14 classes. The total genome territory covered is 71% of the human
genome, slightly less than the ENCODE prediction. This difference may be due to
dataset input and computation discrepancies or may represent ncRNA genes still
awaiting identification and characterization.

GeneCards(R) is a comprehensive online database that provides concise genomic
information on all known and predicted human genes. With over 12 million page
visits per year from hundreds of thousands of unique users worldwide,
GeneCards(R) is accessed by professionals in academia, research hospitals, patent
offices, and leading biotech and pharma companies. GeneCards(R) was developed,
and is continuously enhanced by ongoing research, by the bioinformatics team at
the Department of Molecular Genetics at the Weizmann Institute of Science in
Israel, with principal investigator Professor Doron Lancet, head of the Crown
Human Genome Center, and team leader Marilyn Safran.

"It is wonderful to see how GeneCards(R) allowed us to overcome the great
obstacles of grand unification of ncRNA genes. This allows scientists to make
discoveries on biological and disease-related roles for genes belonging to this
newly open vista of the human genome," said Professor Doron Lancet, Ph.D., The
Ralph D. and Lois R. Silver Professor of Human Genomics, at the Weizmann
Institute of Science.

"The addition of detailed annotated ncRNAs information, while providing the big
picture on ncRNAs is a significant addition to GeneCards(R)," stated Yaron
Guan-Golan, Head of Marketing at LifeMap Sciences. "We have already seen
substantial interest from companies and academic users to access this new
information for their research and product discovery efforts. We believe that
this new information, and the synergies between GeneCards(R), MalaCards, and
LifeMap Discovery(TM) will significantly enhance basic research, and contribute
greatly to the discovery and development of novel diagnostic and therapeutic
products and technologies."

About LifeMap Sciences, Inc.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext